Cargando…
Fertility Preservation in Female Patients with Breast Cancer – a Current Overview
Many premenopausal patients who develop breast cancer have not yet completed their family planning, so measures of fertility protection to preserve their fertile potential would be beneficial. Polychemotherapy causes irreversible damage to the ovarian follicles – irrespective of whether in a neoadju...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2017
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658233/ https://www.ncbi.nlm.nih.gov/pubmed/29093602 http://dx.doi.org/10.1055/s-0043-119543 |
_version_ | 1783273957071257600 |
---|---|
author | Guenther, Veronika Alkatout, Ibrahim Junkers, Wiebe Bauerschlag, Dirk Maass, Nicolai von Otte, Soeren |
author_facet | Guenther, Veronika Alkatout, Ibrahim Junkers, Wiebe Bauerschlag, Dirk Maass, Nicolai von Otte, Soeren |
author_sort | Guenther, Veronika |
collection | PubMed |
description | Many premenopausal patients who develop breast cancer have not yet completed their family planning, so measures of fertility protection to preserve their fertile potential would be beneficial. Polychemotherapy causes irreversible damage to the ovarian follicles – irrespective of whether in a neoadjuvant or adjuvant setting – and this can sometimes result in permanent infertility. Depending on which cytostatic agents are used and on the age-related ovarian reserve of the woman, gonadotoxic risk must be classified as low, moderate or high. Options of fertility preservation include: a) cryopreservation of fertilised or unfertilised oocytes. After ovarian hyperstimulation, mature oocytes are retrieved by transvaginal follicle aspiration, after which they are cryopreserved, either unfertilised or on completion of IVF or ICSI treatment. During b) cryopreservation of ovarian tissue, about 50% of the ovarian cortex of one ovary is resected with the aid of a laparoscopic procedure and cryopreserved. The application of c) GnRH agonists as a medicinal therapy option is an attempt at endocrine ovarian suppression in order to protect oocytes, granulosa cells and theca cells from the cytotoxic effect of chemotherapy. |
format | Online Article Text |
id | pubmed-5658233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-56582332017-10-30 Fertility Preservation in Female Patients with Breast Cancer – a Current Overview Guenther, Veronika Alkatout, Ibrahim Junkers, Wiebe Bauerschlag, Dirk Maass, Nicolai von Otte, Soeren Geburtshilfe Frauenheilkd Many premenopausal patients who develop breast cancer have not yet completed their family planning, so measures of fertility protection to preserve their fertile potential would be beneficial. Polychemotherapy causes irreversible damage to the ovarian follicles – irrespective of whether in a neoadjuvant or adjuvant setting – and this can sometimes result in permanent infertility. Depending on which cytostatic agents are used and on the age-related ovarian reserve of the woman, gonadotoxic risk must be classified as low, moderate or high. Options of fertility preservation include: a) cryopreservation of fertilised or unfertilised oocytes. After ovarian hyperstimulation, mature oocytes are retrieved by transvaginal follicle aspiration, after which they are cryopreserved, either unfertilised or on completion of IVF or ICSI treatment. During b) cryopreservation of ovarian tissue, about 50% of the ovarian cortex of one ovary is resected with the aid of a laparoscopic procedure and cryopreserved. The application of c) GnRH agonists as a medicinal therapy option is an attempt at endocrine ovarian suppression in order to protect oocytes, granulosa cells and theca cells from the cytotoxic effect of chemotherapy. Georg Thieme Verlag KG 2017-10 2017-10-26 /pmc/articles/PMC5658233/ /pubmed/29093602 http://dx.doi.org/10.1055/s-0043-119543 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Guenther, Veronika Alkatout, Ibrahim Junkers, Wiebe Bauerschlag, Dirk Maass, Nicolai von Otte, Soeren Fertility Preservation in Female Patients with Breast Cancer – a Current Overview |
title | Fertility Preservation in Female Patients with Breast Cancer – a Current Overview |
title_full | Fertility Preservation in Female Patients with Breast Cancer – a Current Overview |
title_fullStr | Fertility Preservation in Female Patients with Breast Cancer – a Current Overview |
title_full_unstemmed | Fertility Preservation in Female Patients with Breast Cancer – a Current Overview |
title_short | Fertility Preservation in Female Patients with Breast Cancer – a Current Overview |
title_sort | fertility preservation in female patients with breast cancer – a current overview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658233/ https://www.ncbi.nlm.nih.gov/pubmed/29093602 http://dx.doi.org/10.1055/s-0043-119543 |
work_keys_str_mv | AT guentherveronika fertilitypreservationinfemalepatientswithbreastcanceracurrentoverview AT alkatoutibrahim fertilitypreservationinfemalepatientswithbreastcanceracurrentoverview AT junkerswiebe fertilitypreservationinfemalepatientswithbreastcanceracurrentoverview AT bauerschlagdirk fertilitypreservationinfemalepatientswithbreastcanceracurrentoverview AT maassnicolai fertilitypreservationinfemalepatientswithbreastcanceracurrentoverview AT vonottesoeren fertilitypreservationinfemalepatientswithbreastcanceracurrentoverview |